HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Torsades de pointes — Clinical Guidelines

Overview

Torsades de pointes (TdP) is a specific form of polymorphic ventricular tachycardia characterized by a distinctive twisting of the QRS complexes on the electrocardiogram, often triggered by drug-induced QT interval prolongation 1 2.

Diagnosis

Key Diagnostic Criteria: Polymorphic ventricular tachycardia with a characteristic twisting of QRS complexes on ECG 1.

Recommended Tests: Electrocardiogram (ECG) monitoring to detect QT interval prolongation and TdP 1 2.

Grading: Severity often correlates with clinical presentation and underlying QT interval prolongation 3.

Management

First-Line Treatments:

- Magnesium Sulfate: Intravenous magnesium sulfate is recommended to terminate TdP episodes 1 2. - Avoidance of Triggering Agents: Discontinue or avoid drugs known to prolong QT interval 1 2.

Adjunctive Treatments:

- Cardioversion: For hemodynamic instability, immediate cardioversion may be necessary 1. - Antiarrhythmic Drugs: Consider beta-blockers or other antiarrhythmics if magnesium is ineffective 1.

Special Populations

Elderly: Increased susceptibility to drug-induced QT prolongation and TdP 1 2.

Comorbidities: Patients with existing heart conditions or electrolyte imbalances are at higher risk 1 2.

Key Recommendations

Monitor and Avoid QT-Prolonging Drugs: Regularly monitor patients for QT interval changes and avoid concomitant use of drugs known to prolong QT interval to minimize TdP risk (Evidence: Moderate) 1 2.

Use Magnesium Sulfate for Treatment: Administer intravenous magnesium sulfate as first-line treatment for acute episodes of TdP (Evidence: Moderate) 1 2.

Educate Healthcare Providers: Enhance awareness and knowledge among healthcare providers regarding drugs that can induce TdP, particularly in high-risk populations like the elderly (Evidence: Expert opinion) 6.

Standardize QT Interval Studies: Advocate for standardized methodologies in assessing QT interval prolongation potential of drugs to improve regulatory guidance and patient safety (Evidence: Expert opinion) 7.

References

1 Ji H, Gong M, Gong L, Zhang N, Zhou R, Deng D et al.. Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. Journal of medical Internet research 2025. link 2 Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiology and drug safety 2009. link 3 Sager PT. Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. British journal of pharmacology 2008. link 4 Chiang AY, Bass AS, Cooper MM, Engwall MJ, Menton RG, Thomas K. ILSI-HESI cardiovascular safety subcommittee dataset: an analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc). Journal of pharmacological and toxicological methods 2007. link 5 Martinez JB, Moos DD, Dahlen LL. Droperidol's effect on QT interval. Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses 2006. link 6 Marshall SD, Myles PS. Anaesthetists' knowledge of the QT interval in a teaching hospital. Anaesthesia and intensive care 2005. link 7 Owens RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002. link 8 Maisuls E, Lorber A. Quinidine-induced torsade de pointes suppressed by paroxysmal atrial fibrillation. International journal of cardiology 1987. link90157-4)

Torsades de pointes